Core Viewpoint - A class action lawsuit has been filed against Jayud Global Logistics Limited, alleging that the company's stock experienced a significant decline following an artificial price surge, resulting in substantial losses for investors [1][3]. Group 1: Company Overview - Jayud Global Logistics Limited is headquartered in Shenzhen, China, and provides end-to-end supply chain solutions, including freight forwarding, supply chain management, customs brokerage, and intelligent logistics IT systems [2]. Group 2: Legal Action Details - The class action lawsuit is on behalf of investors who purchased Jayud securities between April 21, 2023, and April 30, 2025 [1]. - Investors have until January 20, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 3: Allegations and Stock Performance - The complaint alleges that Jayud's stock price surged from approximately $1.00 to $8.00 per share in early 2025 due to a "pump-and-dump" scheme orchestrated by insiders or affiliates [3]. - Following this artificial surge, the stock experienced a sharp decline of about 95% on April 2, 2025, leading to significant investor losses [3].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly making false or misleading statements regarding its business operations and prospects during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Telix securities from February 21, 2025, to August 28, 2025 [1]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Allegations Against Telix - Defendants are accused of overstating progress with prostate cancer therapeutic candidates and exaggerating the quality of their supply chain and partners [3]. - The complaint claims that when the true state of Telix's business was revealed, investors experienced significant losses [3]. Group 3: Company Background - Telix Pharmaceuticals is a biopharmaceutical company based in Melbourne, Australia, focusing on developing diagnostic and therapeutic radiopharmaceutical products [2].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025, and they have until January 16, 2026, to seek appointment as lead plaintiff [2]. - The complaint claims that Skye failed to disclose that the efficacy of nimacimab was lower than represented, leading to an overstatement of the drug's clinical and commercial potential [3]. Stock Performance Impact - Following the announcement on October 6, 2025, that the primary endpoint of the Phase 2a study of nimacimab was not met, Skye's stock price fell by $2.85 per share, a decline of 60%, closing at $1.90 [4].

Core Viewpoint - A class action lawsuit has been filed against Six Flags Entertainment Corp. on behalf of investors who purchased shares during the specified Class Period, alleging that the merger with Cedar Fair L.P. was misrepresented regarding the company's operational and capital needs [1][3]. Group 1: Lawsuit Details - The lawsuit claims that the registration statement for the merger did not accurately reflect Six Flags' true operational and capital requirements, despite public assertions of significant investments [3]. - The complaint highlights that undisclosed capital needs were inconsistent with the rationale provided for the merger [3]. Group 2: Stock Performance - Following the merger's closure on July 1, 2024, Six Flags' stock price initially traded above $55 per share but subsequently plummeted to as low as $20, marking a decline of nearly 64% [4]. Group 3: Investor Information - Investors who acquired Six Flags securities during the Class Period have until January 5, 2026, to seek appointment as lead plaintiff representatives [2].

PHILADELPHIA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the “Class Period”). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plainti ...

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc by Berger Montague PC on behalf of investors who purchased shares during the specified Class Period, alleging financial misconduct [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Marex concealed losses and inflated profits through off-balance-sheet entities and fictitious intercompany transactions, as reported by NINGI Research [3]. - Following the allegations, Marex's stock price fell by $2.33, or 6.2%, closing at $35.31, indicating significant investor losses [3]. Group 2: Company Background - Marex Group plc is a London-based global financial services company that specializes in trading, clearing, and risk management [2]. - Berger Montague, the law firm representing the plaintiffs, is known for its focus on complex civil litigation and has recovered over $50 billion for clients over its 55-year history [4].

PHILADELPHIA, Dec. 2, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a le ...

Accessibility StatementSkip Navigation PHILADELPHIA, Dec. 1, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 26, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PCÂ announces that a class action lawsuit against Six Flags Entertainment Corp. (NYSE: FUN) ("Six Flags" or the "Company") has been filed on behalf of investors who purchased or acquired Six Flags shares July 1, 2024 through November 5, 2025 (the "Class Period"), including in connection with the merger between Six Flags and Cedar Fair L.P. (the "Merger"). Investor Deadline: Invest ...

Group 1 - Berger Montague is advising shareholders of Baxter International Inc. regarding an investigation into the Board of Directors for potential breaches of fiduciary duties related to the marketing and sale of the Novum Large Volume Pump [1] - The investigation focuses on whether the Board of Directors properly oversaw the marketing and sale of the Novum LVP, which is used for controlled delivery of intravenous fluids [1] - In July 2025, Baxter announced a voluntary and temporary pause in shipments and planned installations of the Novum LVP [1] Group 2 - Berger Montague is a prominent law firm specializing in complex civil litigation, class actions, and mass torts, with over $2.4 billion in post-trial judgments in 2025 [1] - The firm has recovered over $50 billion for clients and represented classes in various legal areas for over 55 years [1]